Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead
Avalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Avalyn to Participate in the Jefferies Global Healthcare Conference
Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
U.S. IPO Weekly Recap: Biotech, Early-Stage Mining, And Bill Ackman Close Out The April IPO Market
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Avalyn Announces Pricing of Upsized Initial Public Offering
U.S. IPO Weekly Recap: Nuclear Tech, Critical Materials, And More In A 4 IPO Week
U.S. IPO Weekly Recap: Pipeline Swells With Sizable IPO Filings As Metals Royalty Direct Lists